A Phase 2 Proof-of-concept Study to Evaluate the Efficacy and Safety of MEDI3902 in Mechanically Ventilated Patients for the Prevention of Nosocomial Pneumonia Caused by Pseudomonas Aeruginosa
Latest Information Update: 23 Dec 2021
Price :
$35 *
At a glance
- Drugs Gremubamab (Primary)
- Indications Nosocomial pneumonia
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms EVADE
- Sponsors AstraZeneca; MedImmune
- 25 Oct 2020 Primary endpoint (Efficacy of single intravenous (IV) doses of MEDI3902 as measured by signs and symptoms of nosocomial pneumonia caused by P aeruginosa) has not been met.
- 25 Oct 2020 Results presented at the IDWeek 2020.
- 20 Dec 2019 According to European Clinical Trials Database record, this trial is completed in Spain.